Showing posts with label bioprocess. Show all posts
Showing posts with label bioprocess. Show all posts

Monday, March 21, 2016

The Standardization of Single-use Components for Bioprocessing

The focus in the bioprocessing industry is shifting from acceptance of single-use technology to standardization. It is critical that components be included in the standardization discussion. The tubing connector is essential for secure, sterile, leak-free connections between various single-use systems and processes. A user can have the best filter, bag and tubing but this is all pointless if the connector is not reliable, easy-to-use or robust. Improving connector compatibility and interchangeability are great opportunities for standardization, particularly because of complications related to managing inventories.

Inventory Issues


Several inventory issues arise from lack of connector standardization:

• Increased ordering complexity because the user must define which tube set or assembly works with which part of the application. 
• Greater risks of specifying the wrong system or connection, resulting in downtime and last minute adjustments at the end user site.
• Longer lead times because systems suppliers are manufacturing lower volumes of multiple SKUs as opposed to higher volumes of fewer SKUs. This lowers the incentive and likelihood for a manufacturer to stock of these items.
• Increased stocking requirements for end users, including connectors of different genders and other components needed to create make-shift adapters.

Reducing Overhead Costs: Less is More


While overhead cost reductions might be difficult to quantify, they cannot be overlooked. Reduction in SKUs and inventory lowers the cost of managing and maintaining that inventory, which allows capital to be allocated to additional process improvements. One way to help simplify and reduce inventory is to use genderless connectors that enable transitions between tubing of different sizes. Using genderless connections (e.g. CPC’s interchangeable AseptiQuik® G connectors) eliminate the need for reducer fittings elsewhere in the process as the connectors can act as reducers.

Component Standardization


By focusing on the most versatile genderless connectors, component standardization will help bioprocessing companies make the best use of single-use technology. The right connectors will enable end users to:
• Streamline operations with easy-to-use, robust sterile connections
• Eliminate potential ordering mistakes and reduce inventory demands related to gendered connectors • Maintain more flexibility and lessen production bottlenecks with onsite connector assembly 
• Reduce overhead costs, freeing up capital for other projects

Ultimately, standardizing components by incorporating single-use genderless connectors lets end users accomplish more with fewer finished goods, saving time and money, and getting their biopharmaceutical products to market more efficiently. 


Author: Todd Andrews, Global Sales and Business Development Manager, Bioprocessing for CPC – Colder Products Company

The standardization of single-use components for bioprocessing byTodd Andrews, Colder Products Company



Share this article with your social network, just click below to share now!


Thursday, March 3, 2016

Don’t Miss BPI West!

Last chance to register for BPI West is March 9th. Use the code BPIWEST16BL and save $100- Register now!

The clock is ticking. BPI West is just over a week away! Don't miss out on networking with industry experts, scientists and executives, along with emerging and established technology companies. Your registration will gain you access to:

• 700+ global attendees
• 80+ exhibitors highlighting new products and technologies
• 65+ scientific posters showcasing novel research
• 3 thought-leading keynote presentations
• BPI West Theater Presentations
• And More!

Download the brochure for full program details.

PLUS! We're excited to announce that Michael Egholm, President of Pall Biopharmaceuticals joins the upcoming BPI West event in Oakland on March 14th! Join us as he provides an update on the Significant Technology Advances Enabling Integrated Continuous BioProcessing during Monday's The Future of Continuous Processing pre-conference symposia. Best of all, this session is complimentary to all registered attendees!



Can't make it to all 4 days? We've got you covered with special one-day Exposition Hall & Keynotes passes starting at $150! Click here for more information.


Share this article with your social network, just click below to share now!


Monday, February 29, 2016

Innovative Technologies, People, and Organizations Drive the Future of Bioprocessing

By  S. Anne Montgomery, Editor in Chief, BioProcess International 

In the 14 years that BioProcess International (BPI) magazine has been around, the biopharmaceutical industry has experienced a dramatic confluence of technologies, analytics, and regulatory initiatives aimed toward accelerating development and commercialization of life-saving biotherapeutics. Although a number of these topics were “on the radar” before the turn of the century, by the time of BPI’s first issue in January of 2003, they were beginning to be discussed in earnest, and references to “disruptive technologies” began to appear in print, online, and conference discussions across development phases.

As revealed in BPI’s article archive the list is impressive and includes, notably
• single-use technologies
• quality-by-design
• process-analytical technologies
• advanced medicines/cell and gene therapies
• antibody–drug conjugates
• biosimilars and biobetters
• immunotherapies
• combination products
• companion diagnostics
• platform analytics and manufacturing technologies
• product life-cycle development
• continuous processing.

We have watched, too, as those innovations spread across the globe into regions not previously considered to be biomanufacturing hubs and as international regulatory agencies sought to harmonize pathways to approval. Different partnering models have emerged with both long- and short-term goals, but many in response to concerns about supply-chain integrity in an era of life-cycle management.

Presenting information and guidance for sorting through these choices of platforms, technologies, and manufacturing models is the continuing work of technical publications and conference presentations. BioProcess International magazine has always benefited from its close collaboration with the Informa conference groups (IIR/IBC) to create separate but compatible content and presentation vehicles. Many of the magazine’s editorial advisors also have served on the conference advisory panels, for example, and industry trends (and the best people to speak and write about them) identified by one group are shared with the other to bring as consistent a message to our readers and event attendees as possible.

Our two annual flagship events — now called BPI West and BPI — pull these interrelated topics together into week-long programs that you don’t want to miss if you need to stay on top of the latest interpretations of these trends. A quick look at the program for the upcoming BPI West (14–17 March 2016 in Oakland, CA) reveals the ongoing impact of the past decade’s advances on the current biopharmaceutical industry. The opening preconference symposia in themselves reflect key areas of attention: innovative approaches and technologies in process development and manufacturing, cell-therapy commercialization, ADC development, and continuous processing. Many elements of those topics were just promising ideas a decade ago, research topics that “might someday” be brought into commercial viability.

Another example is that the Basic Research and Discovery track of this year’s conference is far from the relatively “siloed” research presentations of the past. Speakers here now will stress the needed overlap of development strategies with early risk analysis and process optimization — with their goals (repeating across product classes and development stages) of shortening the times for lead optimization and transition into manufacturing. Enabling technologies incorporate analytical tools that in themselves introduce new questions: How much information is too much? What are we seeing now of contaminants and particulates in marketed products that we didn’t know were there before, and what does that mean for developers of follow-on products? What statistical knowledge for assessing this wealth of data is now required of those entering the industry that was not deemed necessary before?

I urge you to visit the conference site, download the program, and plan to attend sessions that will help you navigate the current and future worlds of biomanufacturing. Network with your peers, among whom are many veterans who helped build our current industry as well as a younger generation who are introducing fresh insights and new ways of implementing technologies and communication tools.

And as you contribute to advancing this new world biomedical approaches, take a look, also, at BPI’s third biennual awards program categories. Our awards are designed to reflect key milestones in the industry, highlight technologies that are making often-disruptive changes in how biopharmaceutical products and modalities are reaching those who desperately need them, and honor companies and people who are building a new world of healthcare options for both regional and global communities.

I have followed the biopharmaceutical industry as an editor since 1988, and I sometimes take a step back and marvel at how far this work has come. Technologies come and go — and some return again, with problems solved and new challenges revealed. Terminology may look the same, but its connotations are sometimes radically different to new generations. As always, communication is key, but exchange of knowledge must be based on shared understanding of terminology and technologies. Plan to join us in March and continue to contribute to these meaningful discussions. Make your mark on the future of biomanufacturing — we need your voice and we want to hear about your experiences.


Share this article with your social network, just click below to share now!


Monday, February 22, 2016

How to Accelerate Biopharmaceutical Development and Manufacturing


At BioProcess International last October, Ganesh Vedantham, Ph.D., Director, Process and Product Engineering at Amgen moderated a panel to discuss innovation, in technology, products for acceleration of biopharmaceutical development and manufacturing. The evolution in Biopharmaceutical industry business model led by cost structure, geographic dynamics, global, economic realities and policies. And the industry trends in next 3-5 years in business model, cost structure, biopharmaceutical development and manufacturing, geographic dynamics, global realities and policies.

The panelists consisted of:
  • K.V. Subramaniam, MBA, Chief Executive Officer, Reliance Life Sciences
  • Rahul Singhvi, MBA, Chief Operating Officer, Takeda Vaccines
  • Hanne Bak, Ph.D., Senior Director, Purification Development, Regeneron Pharmaceuticals, Inc.
  • Victor Vinci, Ph.D., Chief Scientific Officer and Vice President of Process Development at Cook Pharmica
  • Gregg Nyberg, Ph.D., Director of Cell Sciences and Technologies, Amgen


Share this article with your social network, just click below to share now!


Monday, February 15, 2016

Key Industry Business & Market Trends; From a CMO Perspective


For a sneak peek at the high caliber of content presented at BPI West, we had industry expert Dr. Victor Vinci of Cook Pharmica join us for an exclusive interview.

In this interview, Victor Vinci, Ph.D., Chief Scientific Officer and Vice President of Process Development at Cook Pharmica discusses key trends as they relate to the business and market landscape from a CMO perspective, what the risks are and how as a CMO do you share or mitigate those risks - as well as what that process of sharing and mitigating looks like, and finally he discusses Cook Pharmica and their unique position relative to other CMO's and the strategic direction they are taking.


Interested in learning more? Join us at BPI West - March 14-17 in Oakland, CA. Register before 2/19 with the code BPIWEST16BL and save $300! Click here to activate your savings.


Share this article with your social network, just click below to share now!


Wednesday, February 3, 2016

[Survey] Bioprocessing Efficiency | Enter for a Chance to Win









Maximize Efficiency; Streamline Biopharmaceutical Process Development & Production 

One of the major goals of BPI West it to provide information that you can use to streamline and accelerate process development and production to maximize efficiency from basic research to commercial manufacturing. With that in mind, we would greatly appreciate a few moments of your time to answer the following questions to help us better understand your needs and approaches to accomplishing these goals.


Upon completing the survey, you will be entered into a drawing to win an all-access pass* to BPI West, taking place in Oakland, CA March 14-17, 2016. Learn more about BPI West.

The compiled results of this survey will be distributed as a detailed infographic reportt, depicting the current state and future directions of the biopharmaceutical industry.

We truly value the information you have provided and thank you in advance for taking the time out of your busy day to participate in our survey.

*Offer is not valid for existing or pending registrations, and cannot be retroactively applied. IBC USA & BPI West are not responsible for any hotel or travel costs.


Share this article with your social network, just click below to share now!


Wednesday, January 20, 2016

8 Reasons Why You Can't Miss BPI West | Plus! Register by Friday, 1/22 and Save $400


8 Reasons Why You Can't Afford to Miss BPI West:
1. First and only phase-based format event that fosters the collective sharing ideas, strategies and solutions across departments to improve speed, cost and quality at every stage of development
2. Breakdown the barriers and collaborate across stages of development to achieve end-to-end integration
3. Discover the latest breakthroughs on successfully implementing continuous processes and linking them together to achieve fully continuous processing from cell culture through to drug substance
4. Accelerate the design and development of novel drug substances for next generation therapeutics by integrating candidate selection and early development
5. Develop strategies for fast tracking early stage biologics and managing the life cycle of a break through therapy designated product
6. Speed up and streamline the transition into development by utilizing manufacturability assessments, automation, and QbD in late stage discovery and R&D
7. Implement disruptive technologies and achieve operational excellence to drive manufacturing efficiencies and minimize costs
8. Uncover the future of single-use systems and next generation facility design, modelling and management in current and emerging markets

Want to learn more about the event? Download the brochure.

Register by this Friday, January 22nd and receive up to $400 in savings - Use the code BPIWEST16BL to save.




Share this article with your social network, just click below to share now!


Friday, January 8, 2016

Leaders from Amgen and Celltheon Set to Keynote BPI West

Specialists from every discipline and stage of development aim to achieve the common goals of optimizing speed, reducing cost, and improving quality from basic research to commercialization. What helps the learning curve is to benchmark best practices from the exclusive experience of the top minds in the biopharmaceutical industry.

The leading experts from Amgen and CellTheon will get together at BPI West in Oakland, CA (March 14-17, 2016) to share their exclusive case studies and new data and evaluate the different approaches that are being utilized to streamline and accelerate development and production across:

- Basic Research & Discovery
- Early Stage Process Development & Pre-Clinical Manufacturing
- Late Stage Process Development & Clinical Manufacturing
- Commercial Manufacturing & Beyond

The following keynotes have been announced:



Amita Goel, MSc. Founder, and CEO, Celltheon will be presenting on Innovative Technologies for the Expression of Next Generation Bio Therapeutics;


Rohini Deshpande, Ph.D. Executive Director, Process and Product Development, Amgen will give a talk on End-to-End Integration;



Ran Zheng, Ph.D., Executive Director, Plant Manager, Amgen is joining BPI West with a presentation called “Unleashing the Power of Innovation to Tackle Biomanufacturing's Greatest Challenges, Fuel Growth and Drive Value Creation.”


To see more speakers and to get the most up-to-date brochure, click here. 
Don’t miss the chance to learn the innovative strategies and technologies and help move the pipeline of next generation drug candidates closer to approval!

Register before Friday, January 22nd and save $400 – Simply use the code BPIWEST16BL, to save. 



Share this article with your social network, just click below to share now!


Tuesday, December 15, 2015

BPI West Brochure is Now Available for Download | Save $500 Now, Rates Increase Friday

Break down the barriers between departments and stages of development at BPI West - the industry's first and only phase-based format event! 



BPI West is one-of-a-kind phase-based format is designed to capitalize on the latest approaches and technologies to help move the pipeline of next generation drug candidates closer to approval. Collectively share ideas, strategies and solutions to improve speed, cost and quality from basic research to commercial manufacturing.

Top 3 Reason Why You Can’t Miss BPI West:
  1. Learn how to streamline and accelerate the development to approval process by collaborating at the interfaces of discovery, R&D, process development, and manufacturing
  2. Discover the latest tools, technologies, and strategic approaches to increase efficiency, productivity, and cost savings at every stage of development
  3. Foster the cross-fertilization of new ideas and perspectives to reach new levels of clinical and commercial success

This new format will bring together experts from every discipline and stage of development to achieve the common goals of optimizing speed, reducing cost, and improving quality from basic research to commercialization. Benchmark best practices, hear exclusive case studies and new data presentations at BPI West in Oakland, CA.

Don't forget! This Friday, December 18th is your last chance to save up to $500! Use the code BPIWEST16BL to save - Register here.



Share this article with your social network, just click below to share now!


Thursday, October 1, 2015

Automation should support a 'clear vision for commercial viability' - Brian Hampson


Brian Hampson: automation must support a clear vision for commercially viable manufacturing

By Brian Caine

“Companies must understand that automation should support a clear vision for commercially viable manufacturing and is a tactical approach to support a strategic end,” Brian Hampson ME, vice president of manufacturing development and engineering at PCT, a Caladrius company, told attendees at Cell Therapy Bioprocessing & Commercialization.

Hampson has more than 20 years’ experience in the cell therapy industry and has first-hand experience in the evolution and progress being made within the cell therapy development process. He said that “automation strategies vary with fundamental differences of product”, pointing out several factors need to be considered including:
  • Development by design, as defined by quality – COGS – scale and sustainability
  • Should consider needle-to-needle scope
  • Managing comparability risk
  • Automation must be part of a comprehensive strategy
  • Automation considerations:

He also pointed out the many types of automation to consider:
  • Process automation (closed-loop process control)
  • Task automation 
  • Test automation
  • Factory automation
  • Information:  electronic batch records
  • Execution: manufacturing execution system (MES)

He stressed that “automation must be planned in the context of opportunity and value”. “We all talk about doing everything early, but automation can have a dark side to it,” he said. “You need to be sure what is going on inside the process.”

He warned that automation can also create its own problems, including process black box effect, supply chain risk, complexity, cash and timeline sink, comparability risk and unmitigated automation failure.

Join the conversation on Twitter by following #IBC_CTB15


Share this article with your social network, just click below to share now!


Wednesday, September 23, 2015

Bioprocessing Cell Therapy Products Demands Greater Automation

Cell therapy bioprocessing is undergoing significant developments at the moment. Bioprocess engineers that have developed their skills on vaccine or recombinant protein production will recognise the types of challenges experienced by those attempting to manufacture cell therapies, namely, process development, innovation, operations and process transfer, process characterization and the setting of specifications.

Finding solutions to process and technology cell therapy bottlenecks is the topic of a presentation at the Cell Therapy Bioprocessing BPI Boston, Pre-Conference Symposium from invited speaker Nick Timmins. Nick has previously co-authored a review of cell therapy bioprocessing in BioProcess International 12(3) March 2014 entitled ‘Cell Therapy Bioprocessing Technologies and Indicators of Technological Convergence’.

Increased Sensitivity to the Bioprocess Environment

In the review the authors describe how cells in cell therapy bioprocesses are “biologically dynamic” and highly sensitive to the bioprocess environment in which they are produced. This will have a direct impact on a cell therapies critical quality attributes. In contrast, industrial cell lines that are typically used to produce recombinant proteins are more stable during processing and the final protein product are less directly dependent on the culture and processing environment.

Bioprocess automation mitigates risks in patient-specific therapy production

Bioprocessing technologies used for cell therapy manufacture typically require a higher level of automation which allows for a greater level of control of the bioproduction environment which can impact product CQAs, however it also enables operators to run multiple upstream and downstream protocols simultaneously to produce, what could be, patient-specific therapies. The patient-specific nature of some cell therapies adds in an additional layer of complexity to the processing requirements, not typically found in biomanufacturing, driven by the need to prevent the mishandling or cross contamination of patient tissues. Process automation can help mitigate against some of these risks through ensuring the rigorous control and identification of biological materials as they are produced. More manual process interventions increase the opportunities for errors, contaminations and even abuse.  

The BioProcess International Conference and Exposition will be held on October 26-29, 2015 in Boston and the Cell Therapy Pre-Conference Symposium is scheduled to take place on October 26th.

Join me at #BPIconf
Contact me at nick.hutchinson@parker.com


Dr Nick Hutchinson has a Masters and Doctorate in Biochemical Engineering from University College London, UK where he focused on laboratory tools for rapid bioprocess development and characterization. He then worked at Lonza Biologics in an R&D function investigating novel methods for large-scale antibody purification before moving to an operational role scaling-up and transferring manufacturing processes between Lonza sites in the UK, Spain and USA. Nick now works in Market Development at Parker domnick hunter where his focus is in bringing Parker's strengths in Motion & Control to Bioprocessing. This will enable customers to improve the quality and deliverability of existing and future biopharmaceuticals.


Share this article with your social network, just click below to share now!


Thursday, September 10, 2015

[WEBINAR] Single-Use Equipment Extractables Testing: A Look Forward

With the continued adoption of single-use equipment for the manufacturing of biopharmaceuticals, the discussion on how the industry should handle extractables testing has been prevalent.

Register today to attend GE Healthcare's webinar, Single-use equipment extractables testing: a look forward, and learn about the industry’s progress towards creating a standard for the design and execution of extractables studies for single-use equipment.

The webinar also attempts to place the discussion into a wider context. Assuming the industry adopts such a standard, what problems would this solve and what are the next questions the industry should consider for collaborative discussions and resolution?

Reserve your seat to attend the webinar, held on Tuesday October 6, 2015 during the following three times:
The webinar will be approximately one hour in duration, which includes a live Q&A with the webinar speaker, Dr. Jeffrey Carter, Strategic Projects Leader, Bioprocess Divsion, GE Healthcare Life Sciences.

Space is limited, so reserve your seat today.


Share this article with your social network, just click below to share now!


Monday, August 17, 2015

Overcoming the challenges of high concentration protein formulations


There is a trend within the biopharmaceutical industry for companies to develop formulations for protein drugs with extremely high concentrations. Such formulations provide advantages to both patients and clinicians as they allow biological drugs to be delivered via the sub-cutaneous route of administration rather than by the more traditional intravenous route. Sub-cutaneous delivery allows patients to receive treatment in a clinic or even administer the drug themselves while intravenous infusions tend to require the patient to make a hospital visit which increases the cost of treatment. However, if a patient is able to self-administer the pharmaceutical drug they require to treat a chronic disease then they are more able to lead a normal life which is a tremendous benefit (Highly concentrated protein formulations: Finding solutions for the next generation of parenteral biologics, J Kling, 2014).
The challenge of processing highly concentrated protein drugs
Being able to provide a biopharmaceutical at a formulated concentration of 100 g/L or higher can be a means by which biopharmaceutical companies can gain an advantage over one another in an increasingly competitive marketplace. However, developing such formulations is no trivial task because at high concentrations, protein solutions can become very viscous and difficult to process and the proteins themselves can aggregate. The viscosity of these solutions can challenge filtration equipment and can lead to significant yield losses in the final stages of the processes when the product has its greatest value. Protein aggregation can lead to a reduction in the pharmaceutical’s potency and can even trigger an immune reaction to the drug.

Innovation at the interface with formulations

The topic of high concentration protein formulations will be covered at the BioProcess International Conference & Exposition 2015 to be held on October 26-29 in Boston, MA. Sigma S Mostafa, PhD, Director, Process Development at KBI Biopharma Inc will be chairing a session on ‘Innovation at the Interface with Formulations’. Pfizer are scheduled to present on ‘Challenges of High Concentration Formulations – Dealing with Viscosity and Excipients’ while Mark Moody will present on ‘Opportunities and Challenges of High Concentration Biologics: Case Studies’. The session promises to address some of the key issues manufacturers face when processing concentrated protein solutions.

Have your say

Protein biopharmaceuticals are being formulated to 100 g/L even 200 g/L, however, some have proposed that concentrating to 500 g/L may be desirable. In your opinion, what is the maximum concentration that is required or attainable for protein drug formulations?

Join me at #BPIconf
Contact me at nick.hutchinson@parker.com
Dr Nick Hutchinson has a Masters and Doctorate in Biochemical Engineering from University College London, UK where he focused on laboratory tools for rapid bioprocess development and characterization. He then worked at Lonza Biologics in an R&D function investigating novel methods for large-scale antibody purification before moving to an operational role scaling-up and transferring manufacturing processes between Lonza sites in the UK, Spain and USA. Nick now works in Market Development at Parker domnick hunter where his focus is in bringing Parker's strengths in Motion & Control to Bioprocessing. This will enable customers to improve the quality and deliverability of existing and future biopharmaceuticals.





Share this article with your social network, just click below to share now!


Wednesday, July 22, 2015

Today's Challenges in Cell Therapy


 

Joining us in this Cell Therapy Bioprocessing & Commercialization Podcast is Marty Giedlin, VP of Development at Sangamo BioSciences, Inc. Marty discusses key industry challenges, the evolution of the cell therapy field and where it is headed in the next five years, advancements in technology and much more. Below is a brief excerpt from the podcast, follow the links below to access the complete podcast and transcript.


What are the challenges that you’re experiencing in your industry?

Well, I guess it really depends on what kind of cell therapy you’re talking about. We at Sangamo are processing both autologous T-cells and autologous stem cells. We have the most experience in our T-cell program where we knock out the CCR-5 receptor for HIV in HIV-positive patients. So, the challenges are trying to find that patient population that’s most amenable to this type of therapy, both in viral load, how many years they’ve been in retroviral therapy and that sort of thing. And also finding out which of the CD4 cells – which sub-population – is most important in controlling HIV. So, those are some of the challenges that are facing us there.

With our stem cell program, we have a partnership with CIRM (California Institute for Regenerative Medicine) in California with the City of Hope where we are looking at using CD34 stem cells either from peripheral blood or from bone marrow. What sub-population of those cells are really those that have the capacity for self-renewal over time? Those are the cells that we really want to target to do our gene modification technology.

Then, there are culture conditions to minimize replication, retain stemness and maximizing engraftment with respect to CD34s. And then we’re looking at ways of mobilizing peripheral blood CD34s and how does that affect stemness with respect to CD34s? And then also looking at different ways of bone marrow harvest. So, are there better ways of getting maximal yield to make sure we get enough cells to give back to the patient?

So, for us in the adoptive cell therapy, those are some of the challenges that we’re looking at over the next three to five years.



Share this article with your social network, just click below to share now!


Thursday, July 2, 2015

Single-use technologies enable closed-system bioprocessing

The benefits of single-use technology
Single-use technologies provide a number of benefits over traditional hard-piped equipment and facilities. Five key benefits are described below:
1.    Increased flexibility which allow system changes to be readily implemented during process development, scale-up or while a process is in routine operation.
2.    Reduced risk of contaminations either between batches of the same product or between batches of different products manufactured in the same facility
3.    Reduced or eliminated need for steam-in-place and clean-in-place generating equipment
4.    Shorter facility start-up time
5.    No need for cleaning validation
However, an additional benefit that is attracting an increasing amount of attention is the utilization of single-use technologies to allow closed-system processing.
Why perform closed system processing?
Closed-system processing in single-use technology might be an attractive option for a range of biomanufacturers with different motives. These could include:
·         Cell Therapy manufacturers operating short and simple processes with no method of sterilizing their end-product
·         Vaccine and viral vector manufacturers who find that sterile filtration processes significantly reduce process yields of these large biologics
·         Continuous manufacturers operating processes for many weeks at a time and wanting to avoid a build-up of bioburden within their equipment
·         Any biomanufacturer looking to cut facility running costs by reducing the air handling requirements within processing suites
·         Small-scale, localized, temporary bioproduction facilities manufacturing vaccines close to outbreaks of infectious diseases where local infrastructure is limiting.
Single-use developments allowing for closed-system processing
Pre-irradiated, assembled manifolds and containers are available from a range of suppliers. Operators simply need to install the product-contact consumable and are then ready to start processing.
Single-use bioreactors have been available for some time and are designed, of course, to minimise the risk of microbial ingress. Similarly, single-use mixers and bioprocess containers can be connected to and from with sterile connectors. Sterile disconnectors allow ancillary tubing to be removed while maintaining a sterile boundary around the product. Thermoplastic elastomer tubing can be welded to create flowpaths without compromising sterility and can be sealed to close containers.
The sterilization of product streams and necessary process solutions such as culture media and buffers can be achieved using gamma-irradiated membrane filter capsules. Remember, however, that simply used a sterilizing-grade filter in itself does not guarantee sterility and that validation of the sterile filtration process must be performed to ensure a bioburden-free environment.
For a while, closed-system processing was held back by a lack of suitable technologies for the purification of biologics largely because the need had not been identified or the technology not available. The company I work for has now launched a single-use TFF which avoids the need to clean and store cassettes. At a conference I attended last week Dr James Rusche, Senior VP Research & Development at Repligen described a single-use Protein A chromatography column that had been gamma-irradiated to prevent the build-up of bioburden during continuous harvesting operations.
Of course, because a technology can be gamma-irradiated does not mean it is qualified as sterile, however, if the drivers are there then customers will push vendours to generate this data for all single-use technologies allowing closed-system processing to become a reality for a growing number of processes.
Have your say
Are you driving towards closed system processing? What technology would, if available, make operating in this way more feasible?

Want more on single-use technologies? Meet leading companies in the space at BioProcess International Conference & Exhibition this fall in Boston. Here are the sponsors and exhibitors that will be attending:

Eppendrof
Finesse Solutions, Inc.
GE Healthcare Life Sciences
JSR Life Sciences
Levitronix,
Meissner Filtraion Products
Optek-Danulat Inc.
Qosina
Repligen
Saint-Gobain
SpectrumLabs.com
Pneumatic Scale Angelus
ILC Dover
CPC
Pall Life Sciences
TEK
Nordson Medical
Thermo Fisher Scientific
Beckman Coulter
em-tec Flow Technology (LP)
Kuhner Shaker Inc.
Entegris
WR Grace

Dr Nick Hutchinson

Join me at #BPIconf
Dr Nick Hutchinson has a Masters and Doctorate in Biochemical Engineering from University College London, UK where he focused on laboratory tools for rapid bioprocess development and characterization. He then worked at Lonza Biologics in an R&D function investigating novel methods for large-scale antibody purification before moving to an operational role scaling-up and transferring manufacturing processes between Lonza sites in the UK, Spain and USA. Nick now works in Market Development at Parker domnick hunter where his focus is in bringing Parker's strengths in Motion & Control to Bioprocessing. This will enable customers to improve the quality and deliverability of existing and future biopharmaceuticals.


Share this article with your social network, just click below to share now!


Thursday, June 18, 2015

Might the sun be setting on process-scale chromatography for the purification of biopharmaceuticals?

Browsing through the program for BPI Boston 2015 I was really excited to see Abhinav Shukla is chairing a session in the Recovery & Purification track on novel approaches to non-chromatographic purification. The session will be on Tuesday afternoon starting at 1.25pm.
Like I explained in last week’s blog the subject it’s a subject that is particularly to my heart as it’s the field I worked in as a fresh engineer in my first role upon completing my doctorate.
Bottlenecks in downstream processing
Packed-bed chromatography is, of course, the workhorse of large-scale therapeutic protein purification. The selectivity of chromatography steps especially when operated together as part of an integrated downstream purification train allows very high levels of drug purity to be achieved ensuring patient safety.
The trade-off from a method like this which has such a great ability to resolve different molecular species to give a pure product is that capacity and throughput can be compromised. This was not such an issue during the early days of the industry but as it has developed and bioreactor productivity has increased at a near exponential rate the reliance on chromatography has arguably lead to bottlenecks in purification processes.
The cost of Protein A chromatography
For some within the industry the greatest concern is around Protein A affinity chromagraphy which is an extremely common capture step for monoclonal antibodies once harvested from bioreactors. The extremely high selectivity of Protein A resin means it has a somewhat lower capacity than some alternatives and its high cost of manufacture is reflected in its cost. Though significant advances have been made in Protein A resin technology over the past 20 years there is still significant interest in finding a suitable alternative. The cost of such a consumable means it is imperative biomanufacturers must take care when using and storing the resin to maximize its lifetime.
 Novel methods for therapeutic protein purification
Elastin-like polypeptides (ELP) are fascinating biopolymers that will reversibly transition from soluble molecules to insoluble form at relatively low temperatures. A modest temperature increase will allow an ELP-tagged protein to precipitate out of solution where it can be purified from contaminants using a traditional solid-liquid separation technique such as centrifugation or hollow fibre microfiltration. Resolubilization into a desired solvent or buffer will occur when the temperature of the suspended purified protein is reduced. A great description of the method for purifying ELP-tagged proteins without recourse to chromatography is described in a publication from Ashutosh Chilkoti and others of Duke University.
Author of the 2013 article ‘Emerging Challenges to Protein A’ (BioProcess International. Oct 1, 2013) Pete Gangnon is scheduled to present at the session and hopefully will be sharing more insights into highly innovative antibody purification process he describes in the article. Gangnon highlights two techniques used in combination with one another, firstly chromatin-directed clarification followed by an approach called steric exclusion chromatography which uses polyethylene glycol and hydrophilic particle surfaces. These techniques used with a Capto Adhere chromatography step to complete the purification process gave yields of over 80% while reducing host cell protein levels to <1ppm and aggregate to <0.1%.
What is your experience?
Have you tried non-chromatographic purification methods? How successful was it? Do you think that packed-bed chromatography may have had its day?

Nick Hutchinson
Join me at #BPIconf





















Share this article with your social network, just click below to share now!


Wednesday, June 17, 2015

BPI Boston Announces its 2015 Program

By: Dr. Nick Hutchinson

Hello, welcome and thank-you for visiting our new blog aiming to provide insights and provoke discussion ahead of, and around, the Bioprocess International Conference and Exhibition which will be at Hynes Convention Center, Boston, MA  between the 26th and 29th October 2015.
Many of you will know the event of course, but for those of you who haven’t yet had the pleasure of attending this event previously, it is one of the leading bioprocessing conferences in North America and indeed attracts delegates (including myself), presenters and exhibitors from all over the globe.
If you take a moment to review the conference program you’ll see the reason why. The conference will have 6 tracks covering up- and down-stream processing, manufacturing strategies, analytical and formulation & quality, early phase biologics. This year there will be a new track on drug product manufacturing & fill-finish processing. Each session is chaired by a leader in their field who pulls together presentations addressing real industry problems that delegates can learn from and theb take this information back to their organizations to help them develop, manufacture and commercialize their biopharmaceutical products.
In addition, delegates can attend the pre-conference symposia on Monday, October 26 and will have access to the ever popular BPI Theater featuring, amongst many other things, an “Ask the Regulators” Open Forum and a Fireside Chat session focussed on the key question of how we can accelerate biopharmaceutical development and manufacturing?
There will be a Town Hall Forum Discussion addressing the crucial question of Single-Use Standardization and feature representatives from a range of industry bodies including BPOG, BPSA, PDA, ASTM and ASME/BPE.
Of course, if you need them, there are many other reasons to attend the conference such as over 150 exhibitors and over 100 posters. The opportunities to network with your industry peers are huge.
To help you prepare for the event I’ll be posting about selected topics and key themes from the conference to provide you with background and insights on the subject matter so that you can come prepared to develop collaborations and engage in discussions.
Next blog I’ll be taking a look at a subject close to my heart which is novel approaches for non-chromatographic purification processes. My first role out of college was precisely in this area in order to reduce bottlenecks in downstream processing caused by ever higher product titres being achieved upstream. I hope you’ll provide feedback and share your experiences for the benefit of other delegates.
About the Author: Dr Nick Hutchinson has a Masters and Doctorate in Biochemical Engineering from University College London, UK where he focused on laboratory tools for rapid bioprocess development and characterization. He then worked at Lonza Biologics in an R&D function investigating novel methods for large-scale antibody purification before moving to an operational role scaling-up and transferring manufacturing processes between Lonza sites in the UK, Spain and USA. Nick now works in Market Development at Parker domnick hunter where his focus is in bringing Parker's strengths in Motion & Control to Bioprocessing. This will enable customers to improve the quality and deliverability of existing and future biopharmaceuticals.
Join me at #BPIconf


Share this article with your social network, just click below to share now!